Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Modulation of Network Plasticity Opens Novel Therapeutic Possibilities in Cancer, Diabetes, and Neurodegeneration

Kerestély M., Narozsny I., Szarka L., Veres DV., Csermely P., Keresztes D.

Narrative Review on Neuroinflammation, published in Adv Sci (Weinh) (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Adv Sci (Weinh) (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41618842
PMCID
PMC12948214
DOI
10.1002/advs.202522532
Citations
1

Abstract (original English)

Cellular plasticity is crucially important in cancer-induced cell reprogramming, as well as in regeneration therapies in diabetes, Alzheimer's, and Parkinson's diseases. Protein-protein interaction, signaling, and gene regulatory networks are increasingly used to describe plasticity-induced cellular adaptation in disease progression. This review delineates how network analysis of cell plasticity leads to novel therapy options against 1) cancer progression; 2) epithelial-mesenchymal transition-induced metastases; 3) cancer stem cells, and 4) pre-existent drug-resistant cells. Network plasticity-designed sequential and differentiation therapies are also outlined. 55 plasticity-related cancer drug targets are listed, where 20 have already approved drugs, 9 have investigational drugs, and 26 are drug target candidates. The recent expansion of plastic network-driven pancreatic beta cell and neuron regeneration therapies is described in diabetes, as well as in Alzheimer's and Parkinson's diseases, respectively. Finally, six major network-related research gaps and promising future research areas are outlined, including the discovery of plasticity-related cancer signaling pathways and cross-talks, cancer resensitization therapies, and the use of recently available proteome-wide network data and models to find novel cancer cell differentiation cocktails, drug targets, proper timing, and

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansNeoplasmsNeurodegenerative DiseasesDiabetes MellitusSignal TransductionGene Regulatory NetworksCellular ReprogrammingCell Plasticity

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research